ClinicalTrials.gg

Program

emicizumab

Its studies are mostly in Hemophilia A, led by 2 companies.

Furthest: phase 4, since Nov 20, 201713 company-led studies, 4 open or runningNext primary completion: Nov 19, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche123 open or runningphase 4since Nov 20, 2017Dec 2, 2015Nov 19, 2026phase 4 · NCT05181618
Sanofi11 open or runningphase 4since Nov 17, 2023Nov 17, 2023May 28, 2028phase 4 · NCT06145373

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 2, 2015First study: phase 3 study in Hemophilia ANew to Hoffmann-La RocheHoffmann-La Roche · NCT02622321 · 113 enrolled · United States, Australia, Costa Rica and more
  2. Jun 7, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT02795767 · 88 enrolled · United States, Costa Rica, France and more
  3. Jul 26, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT02847637 · 152 enrolled · United States, Australia, Costa Rica and more
  4. Dec 21, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03020160 · 48 enrolled · United States, Australia, Belgium and more
  5. Jun 15, 2017Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03191799 · 195 enrolled · Australia, Belgium, Brazil and more
  6. Oct 17, 2017Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03315455 · 85 enrolled · China, Hong Kong, Malaysia and more
  7. Nov 20, 2017Phase 4 study in Hemophilia AHoffmann-La Roche · NCT03361137 · 14 enrolled · United States
  8. Dec 13, 2017Phase 1 study in Hemophilia AHoffmann-La Roche · NCT03380780 · 16 enrolled · China
  9. Nov 7, 2019Phase 3 study in Hemophilia AHoffmann-La Roche · NCT04158648 · 73 enrolled · United States, Belgium, Canada and more
  10. Jun 11, 2020Phase 3 study in Hemophilia AHoffmann-La Roche · NCT04431726 · 55 enrolled · United States, Australia, Austria and more
  11. Dec 6, 2021Phase 4 study in Hemophilia AHoffmann-La Roche · NCT05181618 · 136 enrolled · United States, Brazil, Canada and more
  12. Nov 17, 2023Sanofi's first study: phase 4 study in Hemophilia ANew to SanofiSanofi · NCT06145373 · 20 planned · United States, Taiwan
  13. May 22, 2025Phase 3 study in von Willebrand Disease, Type 3Hoffmann-La Roche · NCT06998524 · 75 planned · United States, Belgium, Canada and more
  14. Nov 16, 2026Primary completion moved from 2027-04-30 to 2027-10-06Date moved laterphase 3 · +5 months · NCT06998524

Ahead

  1. Nov 19, 2026Primary completion: phase 4 study in Hemophilia AHoffmann-La Roche · NCT05181618
  2. Oct 6, 2027Primary completion: phase 3 study in von Willebrand Disease, Type 3Hoffmann-La Roche · NCT06998524
  3. May 28, 2028Primary completion: phase 4 study in Hemophilia ASanofi · NCT06145373

TargetBeta

F10 →F9 →read by rule
“Coagulation factor IX and X other”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06998524von Willebrand Disease, Type 3 · United States, Belgium, Canada and more3RecruitingHoffmann-La RocheOct 6, 202775
NCT06145373Hemophilia A · United States, Taiwan4RecruitingSanofiMay 28, 202820
NCT05181618Hemophilia A · United States, Brazil, Canada and more4Active, not recruitingHoffmann-La RocheNov 19, 2026136
NCT04431726Hemophilia A · United States, Australia, Austria and more3Active, not recruitingHoffmann-La RocheMay 22, 202355
NCT04158648Hemophilia A · United States, Belgium, Canada and more3CompletedHoffmann-La RocheOct 30, 202173
NCT03380780Hemophilia A · China1CompletedHoffmann-La RocheSep 18, 201816
NCT03361137Hemophilia A · United States4TerminatedHoffmann-La RocheMar 13, 202014
NCT03315455Hemophilia A · China, Hong Kong, Malaysia and more3CompletedHoffmann-La RocheAug 3, 202285
NCT03191799Hemophilia A · Australia, Belgium, Brazil and more3CompletedHoffmann-La RocheNov 19, 2020195
NCT03020160Hemophilia A · United States, Australia, Belgium and more3CompletedHoffmann-La RocheDec 15, 201748
NCT02847637Hemophilia A · United States, Australia, Costa Rica and more3CompletedHoffmann-La RocheSep 15, 2017152
NCT02795767Hemophilia A · United States, Costa Rica, France and more3CompletedHoffmann-La RocheApr 30, 201888
NCT02622321Hemophilia A · United States, Australia, Costa Rica and more3CompletedHoffmann-La RocheOct 25, 2016113

How it is read

Names in the registry

  • “Emicizumab”, 13 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.